Healthcare Organizations Rally Together to Help Highland Park Shooting Survivor

Elevate Care calls on area healthcare partners to make $5,000 matching donations SKOKIE, Ill.–(BUSINESS WIRE)–#HealthcarePartnersforHighlandPark–Healthcare operators and partners across Chicagoland are coming together to help Aiden McCarthy, a 2-year-old boy who lost both of his parents in the Highland Park 4th of July parade shooting. Using #HealthcarePartnersforHighlandPark, Elevate Care started this movement feeling the desire … [Read more…]

 InnoCare Announces Approval of Clinical Trial of Novel Targeted Protein Degrader ICP-490 in China

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the company has received Investigational New Drug (IND) approval of clinical trial from the NMPA (National Medical Products Administration) for its novel targeted protein degrader ICP-490 for the treatment of multiple myeloma (MM) and … [Read more…]

Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies

– Provides additional opportunity for Exelixis to further expand its biotherapeutics development pipeline by combining its tumor-specific targeting approaches with Ryvu’s STING agonist technology, which has best-in-class potential – ALAMEDA, Calif. & KRAKOW, Poland–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) and Ryvu Therapeutics S.A. (“Ryvu”) (Warsaw Stock Exchange: RVU) today announced that the companies have entered into … [Read more…]

Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Protein

A sub-analysis of the Phase 3 LIVE-AIR study of lenzilumab showed a strong correlation between C-reactive protein (CRP) and outcomes with lenzilumab treatment with the greatest clinical benefit experienced by patients with baseline CRP<150 mg/L In these patients, likelihood of survival without mechanical ventilation (SWOV) was achieved in 90% of LIVE-AIR patients treated with lenzilumab … [Read more…]

iHealthScreen Inc. is Awarded US Patent on Late Age-related Macular Degeneration (AMD) Prediction Model, which is based on AI and Color Fundus Imaging

iHealthScreen is the first company that developed the late AMD prediction model and was awarded a patent by USPTO NEW YORK–(BUSINESS WIRE)–#AI—iPredictTM late AMD prediction model provides a fully automated prediction score for age-related macular degeneration (AMD), and identifies the individuals who are at risk of developing late AMD in 1 year, 2-year or 5-year. … [Read more…]

CANbridge Forms Scientific Advisory Board to Guide Global Development of CAN106 in Complement-mediated Diseases

CAN106 Phase 1 results showed rapid and potent C5 inhibition, complete and sustained blockade of complement activity Data presented at European Hematology Association 2022 Congress and 14th International Conference on Complement Therapeutics CAN106 in Phase 1b/2 study of paroxysmal nocturnal hemoglobinuria in China Shows potential for treating other complement-mediated diseases BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge … [Read more…]

Slingshot Biosciences, Inc. Partners With Chameleon Science to Distribute Synthetic Cells Throughout Australia, New Zealand & Singapore

EMERYVILLE, Calif.–(BUSINESS WIRE)–SLINGSHOT BIOSCIENCES, INC., the developers of synthetic cells, today announced they have extended their distribution channel through a new agreement with Chameleon Science. Chameleon Science is an innovative new company specializing in the development and distribution of emerging technologies in Life Sciences. The Chameleon team has over 25 years of experience in the … [Read more…]

DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199

MINNEAPOLIS–(BUSINESS WIRE)–DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Company’s Phase 2/3 ReMEDy2 trial studying the use of the Company’s product candidate, DM199, to treat acute … [Read more…]

DermTech Joins PeDRA Corporate Council, Supporting Efforts to Address Pediatric Skin Diseases

LA JOLLA, Calif.–(BUSINESS WIRE)–DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its membership in the Corporate Council of the Pediatric Dermatology Research Alliance (PeDRA). PeDRA is a nonprofit research network with the mission to create, inspire and sustain research to prevent, … [Read more…]